<DOC>
	<DOC>NCT03069963</DOC>
	<brief_summary>Primary Objective: Pharmacodynamics: assessment by pH metry of the change in gastric pH (antacid activity) of Z0063, in comparison to the effect of Gaviscon Double Action Tablets, in healthy adult subjects. Secondary Objective: Safety: assessment of the clinical safety of Z0063, and Gaviscon Double Action Tablets, in healthy adult subjects.</brief_summary>
	<brief_title>PH Metry Study to Compare the Antacid Activity of Z0063 Versus Gaviscon Double Action Tablets, in Healthy Adult Subjects</brief_title>
	<detailed_description>The maximal total study duration per subject is 5 weeks and 1 day.</detailed_description>
	<mesh_term>Gastroesophageal Reflux</mesh_term>
	<mesh_term>Antacids</mesh_term>
	<mesh_term>Alginate, aluminium hydroxide, magnesium trisilicate, sodium bicarbonate drug combination</mesh_term>
	<mesh_term>Almagate</mesh_term>
	<mesh_term>Aluminum Hydroxide</mesh_term>
	<mesh_term>Magnesium Hydroxide</mesh_term>
	<criteria>Inclusion criteria : Male or female subjects, between 18 and 55 years of age, inclusive. Body weight between 50.0 and 100.0 kg, inclusive, if male, and between 40.0 and 90.0 kg, inclusive, if female, body mass index between 18.0 and 28.0 kg/m2, inclusive. Certified as healthy by a comprehensive clinical assessment (detailed medical history and complete physical examination). Normal vital signs, electrocardiogram (ECG) and laboratory parameters. Subject has to accept a gastric probe. Exclusion criteria: Any history or presence of clinically relevant abnormalities at screening which could interfere with the objectives of the study or the safety of the subject's participation. Blood donation, any volume, within 2 months before inclusion. History or presence of drug or alcohol abuse. Smoking more than 5 cigarettes or equivalent per day, unable to stop smoking during the study. If female, pregnancy (defined as positive betahuman chorionic gonadotropin [Î²HCG] blood test), breastfeeding. Any medication (including St John's Wort) within 14 days before inclusion, with the exception of hormonal contraception or menopausal hormone replacement therapy; any vaccination within the last 28 days and any biologics (antibody or its derivatives) given within 4 months before inclusion. Any subject in the exclusion period of a previous study according to applicable regulations. Any subject who cannot be contacted in case of emergency. Positive result on any of the following tests: hepatitis B surface (HBs Ag) antigen, antihepatitis C virus (antiHCV) antibodies, antihuman immunodeficiency virus 1 and 2 antibodies (antiHIV1 and antiHIV2 Ab). Positive result on urine drug screen. Positive alcohol breath test. Known hypersensitive to alginates, products or formulation excipients, and/or to any component of the standardized meal. Any subject with difficulty in chewing and swallowing. Any subject with strong gag reflex. Any intake of aluminium and magnesium containing antacids or other alginatecontaining medicinal products within 14 days before inclusion. The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>